Department of Medical Oncology, Centro Hospitalar Universitário do Algarve, Rua Leão Penedo, Faro, Portugal.
CBIOS - Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisboa, Portugal.
Curr Med Res Opin. 2022 Aug;38(8):1379-1382. doi: 10.1080/03007995.2022.2096334. Epub 2022 Jul 13.
Tumor-infiltrating lymphocytes (TILs) have shown prognostic value in breast cancer. This study evaluated the TILs scores in 186 Portuguese patients diagnosed with early breast cancer, with special focus on HER2 subtype. Stromal TILs were scored on the core needle biopsies, as well as in the resected specimen in HER2+ patients submitted to neoadjuvant treatment with trastuzumab and pertuzumab. TILs were higher in tumors with negative hormone receptor status and HER2 amplifications, and in triple-negative breast cancer. In HER2+ patients treated with dual anti-HER neoadjuvant therapy, the TILs score on the surgical specimen was generally lower than in the biopsy.
肿瘤浸润淋巴细胞（TILs）在乳腺癌中显示出预后价值。本研究评估了 186 名葡萄牙早期乳腺癌患者的 TILs 评分，特别关注 HER2 亚型。在接受曲妥珠单抗和帕妥珠单抗新辅助治疗的 HER2+患者中，对核心针活检和切除标本中的基质 TILs 进行了评分。在激素受体状态阴性和 HER2 扩增的肿瘤以及三阴性乳腺癌中，TILs 更高。在接受双重抗 HER 新辅助治疗的 HER2+患者中，手术标本中的 TILs 评分通常低于活检。
